HLHao Li

Hao Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hao Li has a total of 318 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The GNB3 C825T Polymorphism Is Associated With Decreased Risk of Recurrence of Large‐Artery Atherosclerotic Acute Ischemic Stroke

    by Ran Yan, Xin Qiu, Yalun Dai, Kaixuan Yang, Hongqiu Gu, Yong Jiang, Si Cheng, Xia Meng, Yilong Wang, Xingquan Zhao, et al.

    Background: GNB3 C825T polymorphism affects G protein–coupled receptor signaling, influencing platelet function, inflammation, and cardiovascular risk. This study aimed to investigate the unknown effects of the GNB3 C825T polymorphism on recurrent stroke risk in large‐artery atherosclerosis and its potential interaction with antiplatelet therapy. Methods: Using the CNSR‐III (Third China National Stroke Registry) data, we analyzed 1233 patients with large‐artery atherosclerotic acute ischemic stroke enrolled within 72 hours of onset. Whole‐genome sequencing was performed to identify the GNB3 C825T polymorphism. Cox regression analysis was used to assess its association with 1‐year recurrent ischemic stroke after adjusting for vascular risk factors. Associations with antiplatelet regimens and mediating effects of inflammatory biomarkers in the overall cohort were also evaluated. Results: Carriers of the GNB3 825T‐allele (CT/TT, 72.7%) exhibited a significantly lower risk of 1‐year recurrent ischemic stroke than noncarriers (adjusted hazard ratio, 0.67 [95% CI, 0.48–0.93]; P =0.02). In exploratory analyses, the association was observed in the aspirin monotherapy subgroup, but the interaction with aspirin use was not significant. Elevated baseline interleukin‐6 partially attenuated this genetic protection in the overall cohort (mediation proportion, –9.82%; P =0.02). Conclusions: The GNB3 825T‐allele was associated with a reduced risk of recurrent stroke in patients with large‐artery atherosclerotic acute ischemic stroke. In exploratory analyses, this association was observed in the aspirin monotherapy subgroup; however, the formal interaction with aspirin use was not statistically significant. These findings support a potential prognostic role of the GNB3 C825T polymorphism and warrant further validation in independent cohorts.

  • Open Access

    Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial

    by Shuya Li, Xuechun Wang, Baoyu Feng, Hao Li, Yongjun Wang

    Background and objectives: Loberamisal, a novel agent that dissociates the post-synaptic density protein 95/neuronal nitric oxide synthase complex and potentiates the α2-containing γ-aminobutyric acid type A receptors, is a potential neuroprotectant that is effective in preclinical studies for acute ischaemic stroke. This trial aims to demonstrate the efficacy and safety of intravenous loberamisal in patients with acute ischaemic stroke (AIS) within 48 hours of onset. Methods and design: The LAIS (Loberamisal for Acute Ischaemic Stroke) trial is a multicentre, prospective, randomised, double-blind, placebo-controlled phase 3 trial. A total of 998 eligible patients will be randomly assigned to receive either loberamisal or placebo in a 1:1 ratio. Outcomes: The primary efficacy outcome is proportion of individuals achieving an excellent functional outcome, defined as modified Rankin Scale (mRS) 0–1 at 90 days. Secondary efficacy outcomes include favourable functional outcome (defined as an mRS score of 0 in patients with a baseline NIHSS score of 4 to 7; an mRS score of 0 to 1 in patients with a baseline NIHSS score of 8 to 14; and an mRS score of 0 to 2 in patients with a baseline NIHSS score of 15 to 25), distribution of mRS at 90 days, patients with ≥4 points reduction in National Institutes of Health Stroke Scale score from baseline at 10 days and 30 days, and Barthel Index ≥95 at 90 days. Safety outcomes were adverse events. Exploratory outcomes include the incidence of depressive and anxiety symptoms at 90 days. Discussion: The LAIS trial will evaluate the potential of loberamisal as a novel neuroprotectant in acute ischaemic stroke. Trial registration number: NCT06517173 .


  • Open Access

    Deep WGS-based STROMICS reference panel enhances genotype imputation in Chinese population

    by Zhe Xu, Si Cheng, Xingchen Lin, Yanfeng Shi, Jie Zhang, Yang Liu, Jinxi Lin, Yong Jiang, Zixiao Li, Yilong Wang, et al.

    Genotype imputation is essential for medical genomics studies. Herein, we present the STROMICS imputation reference panel, constructed from high-depth whole-genome sequencing (WGS) data of 10,241 Chinese individuals. It includes 53,061,655 single-nucleotide variants and insertion-deletions, spanning 22 autosomes and the X chromosome. Imputation performance of the STROMICS and seven other reference panels was compared using WGS data from 159 individuals. STROMICS panel outperformed others in imputation quality, and in genome-wide population- and individual-level accuracy. Validation using 301 Chinese individuals from the 1000 Genomes Project demonstrated STROMICS achieving high imputation accuracy. Among the three Chinese subgroups, the STROMICS reference panel yielded the highest accuracy in Han Chinese in Beijing samples. Notably, STROMICS outperformed all the other panels for the insertion-deletion imputation. When imputing stroke-risk variants and their closely linked variants with STROMICS, only a small statistically significant difference in sensitivity was observed between diseased and healthy individuals for variants closely linked to stroke-risk variants. Furthermore, calculated using pruned variants, the genetic distances between diseased and healthy groups remained largely unchanged before and after imputation. Collectively, these findings indicate that the source material used to construct the STROMICS reference panel has minimal impact on its imputation performance. Finally, we demonstrated high accuracy of STROMICS for genotype imputation in the X-unique region. In conclusion, the STROMICS panel provides a high-quality reference for imputing genotypes across autosomes and the X chromosome in the Chinese population.

  • Open Access

    Loberamisal injection for the treatment of acute ischaemic stroke: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial

    by Baoyu Feng, Hao Li, Shuhong Xu, Jian Li, Yilong Wang, Xingquan Zhao, Yan Wei, Xiaohua Xiao, Suping Wang, Yongjun Wang, et al.

    Background and aims: Loberamisal is a small-molecule agent that inhibits the nNOS-postsynaptic density protein 95 coupling and enhances α2-containing γ-aminobutyric acid type A receptor, which has been shown effective in animal studies. This trial aimed to investigate its safety and therapeutic efficacy in patients with acute ischaemic stroke (AIS) within 48 hours of symptom onset. Methods: Patients were randomly assigned in a 1:1:1:1 ratio to one of four groups: a low-dose loberamisal group (20 mg/dose), a medium-dose group (40 mg/dose), a high-dose group (60 mg/dose) or a placebo group. All patients received a continuous intravenous infusion treatment once a day for 10 days (60±10 min/dose). The primary efficacy outcome was the proportion of patients achieving an excellent functional outcome (a modified Rankin Scale score of 0–1 at 90 days). The primary safety outcome was the incidence of adverse events (AEs). Results: A total of 240 patients were randomised, of whom 224 received study treatment from 4 June 2023 to 18 November 2023. The proportion of patients with excellent functional outcome was highest in the medium-dose group (76.7%, 46/60), followed by the high-dose group (70.0%, 42/60), the low-dose group (67.8%, 40/59) and the placebo group (60.7%, 37/61) (p=0.164). Regarding safety, 210 patients experienced at least one AE, with incidences of 80.0% (48/60), 88.3% (53/60) and 91.5% (54/59) in the high, medium and low-dose loberamisal groups, respectively, and 90.2% (55/61) in the placebo group (p=0.260). Conclusions: Loberamisal injection was well tolerated in patients with AIS within 48 hours of symptom onset in China. The efficacy and optimal dosage of loberamisal for AIS need prospective validation. Trial registration number: ChiCTR2400081662, NCT06429384 .


  • Open Access

    Dual antiplatelet therapy with ticagrelor vs clopidogrel in patients with TIA or minor stroke with or without symptomatic carotid artery stenosis: a post hoc analysis of the CHANCE-2 trial

    by Xuewei Xie, Jing Jing, Anxin Wang, Qin Xu, Xingquan Zhao, Jinxi Lin, Pan Chen, Yong Jiang, Yilong Wang, Hao Li, et al.

    Background and purpose: Symptomatic internal carotid artery stenosis (sCAS) is an essential cause of transient ischaemic attack (TIA) or minor stroke. We aimed to evaluate whether the superiority of aspirin-ticagrelor over aspirin-clopidogrel varies between patients with sCAS or not. Methods: This was a post-hoc analysis of the High-Risk Patients with Acute Nondisabling Cerebrovascular Events-II (CHANCE-2) trial, all of which were CYP2C19 loss-of-function alleles carriers. The primary exposures of interest were the treatment group and sCAS status. The primary efficacy endpoint was the new stroke assessed within 90 days. Results: A total of 5920 (92.3%) from 6412 were analysed, including 197 (3.3%) with sCAS and 5723 (96.7%) without sCAS. Stroke recurrence occurred in 13 (12.15%) and 11 (12.22%) patients with sCAS who received aspirin-ticagrelor and aspirin-clopidogrel, respectively (adjusted HR, 1.04; 95% CI, 0.46 to 2.36; p=0.930). Among patients without sCAS, there were 158 cases (5.52%) of new strokes in the aspirin-ticagrelor group and 222 cases (7.76%) in the aspirin-clopidogrel group (HR, 0.70; 95% CI, 0.57 to 0.86; p=0.0006). The treatment-by-sCAS subtype was not significant (p=0.405). Conclusions: Genotype-guided dual antiplatelet treatment with aspirin-ticagrelor may be beneficial for preventing recurrent strokes in patients without sCAS; however, it appears less effective in those with sCAS. No significant interaction was found between the treatment and sCAS subtypes. Trial registration number: NCT04078737 .


  • Open Access

    Predicting functional outcome in ischemic stroke patients using genetic, environmental, and clinical factors: a machine learning analysis of population-based prospective cohort study

    by Siding Chen, Zhe Xu, Jinfeng Yin, Hongqiu Gu, Yanfeng Shi, Cang Guo, Xia Meng, Hao Li, Xinying Huang, Yong Jiang, et al.

    Ischemic stroke (IS) is a leading cause of adult disability that can severely compromise the quality of life for patients. Accurately predicting the IS functional outcome is crucial for precise risk stratification and effective therapeutic interventions. We developed a predictive model integrating genetic, environmental, and clinical factors using data from 7819 IS patients in the Third China National Stroke Registry. Employing an 80:20 split, we randomly divided the dataset into development and internal validation cohorts. The discrimination and calibration performance of models were evaluated using the area under the receiver operating characteristic curves (AUC) for discrimination and Brier score with calibration curve in the internal validation cohort. We conducted genome-wide association studies (GWAS) in the development cohort, identifying rs11109607 (ANKS1B) as the most significant variant associated with IS functional outcome. We employed principal component analysis to reduce dimensionality on the top 100 significant variants identified by the GWAS, incorporating them as genetic factors in the predictive model. We employed a machine learning algorithm capable of identifying nonlinear relationships to establish predictive models for IS patient functional outcome. The optimal model was the XGBoost model, which outperformed the logistic regression model (AUC 0.818 versus 0.756, P < .05) and significantly improved reclassification efficiency. Our study innovatively incorporated genetic, environmental, and clinical factors for predicting the IS functional outcome in East Asian populations, thereby offering novel insights into IS functional outcome.


  • Derivation and Validation of a Scoring System for Predicting Poor Outcome After Posterior Circulation Ischemic Stroke in China

    by Jialei Yang, Xiaoyu Lin, Anxin Wang, Xia Meng, Xingquan Zhao, Jing Jing, Yijun Zhang, Hao Li, Yongjun Wang

    Guidelines for posterior circulation ischemic stroke (PCIS) treatment are lacking and outcome prediction is crucial for patients and clinicians. We aimed to develop and validate a prognostic score to predict the poor outcome for patients with PCIS. The score was developed from a prospective derivation cohort named the Third China National Stroke Registry (August 2015-March 2018) and validated in a spatiotemporal independent validation cohort (December 2017-March 2023) in China. Patients with PCIS with acute infarctions defined as hyperintense lesions on diffusion-weighted imaging were included in this study. The poor outcome was measured as modified Rankin scale (mRS) score 3-6 at 3 months after PCIS. Multivariable logistic regression analysis was used to identify predictors for poor outcome. The prognostic score, namely PCIS Outcome Score (PCISOS), was developed by assigning points to variables based on their relative β-coefficients in the logistic model. The PCISOS was derived from 3,294 patients (median age 62 [interquartile range (IQR) 55-70] years; 2,250 [68.3%] men) and validated in 501 patients (median age 61 [IQR 53-68] years; 404 [80.6%] men). Among them, 384 (11.7%) and 64 (12.8%) had poor outcome 3 months after stroke in respective cohorts. Age, mRS before admission, NIH Stroke Scale on admission, ischemic stroke history, infarction distribution, basilar artery, and posterior cerebral artery stenosis or occlusion were identified as independent predictors for poor outcome and included in PCISOS. This easy-to-use integer scoring system identified a marked risk gradient between 4 risk groups. PCISOS performed better than previous scores, with an excellent discrimination (C statistic) of 0.80 (95% CI 0.77-0.83) in the derivation cohort and 0.81 (95% CI 0.77-0.84) in the validation cohort. Calibration test showed high agreement between the predicted and observed outcomes in both cohorts. PCISOS can be applied for patients with PCIS with acute infarctions to predict functional outcome at 3 months post-PCIS. This simple tool helps clinicians to identify patients with PCIS with higher risk of poor outcome and provides reliable outcome expectations for patients. This information might be used for personalized rehabilitation plan and patient selection for future clinical trials to reduce disability and mortality.


  • Open Access

    Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial

    by Shuya Li, Runqi Wangqin, Yuesong Pan, Aoming Jin, Hao Li, Lee H Schwamm, Marc Fisher, Bruce C V Campbell, Mark W Parsons, Ziran Wang, et al.

    Background The benefit of intravenous alteplase in acute ischaemic stroke (AIS) is time-dependent. Tenecteplase is non-inferior to alteplase among patients with AIS. We aimed to delineate the association of the stroke onset to treatment time (OTT) with tenecteplase compared with alteplase on therapeutic benefit and clinical risks. Methods This is a post hoc analysis of the Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-2 an open-label, randomised, controlled, non-inferior trial. A total of 1430 AIS within 4.5 hours onset at 53 sites in China from 12 June 2021 to 29 May 2022 were randomly assigned (1:1) to receive either tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg. The primary efficacy outcome was the proportion of participants with a modified Rankin Scale score of 0–1 at 90 days. A post hoc subgroup analysis was conducted with the OTT divided into three intervals (0–90 min, 91–180 min and 181–270 min). The primary safety outcome was symptomatic intracranial haemorrhage within 36 hours post-thrombolytic treatment. Results Treatment was initiated within 270 min of stroke onset in 1412 patients who were randomly allocated to either tenecteplase (n=707) or alteplase (n=705). The OR of primary efficacy outcome was similar as OTT increased (p=0.84). Adjusted odds of an excellent functional outcome were 0.99 (95% CI 0.37 to 2.67) for 0–90 min, 1.23 (95% CI 0.88 to 1.71) for 91–180 min and 1.21 (95% CI 0.88 to 1.65) for 181–270 min. All were in favour of the tenecteplase group. Meta-analysis of 2949 patients yielded a pooled risk difference of 5.54 (95% CI −0.18 to 11.26; p=0.82) in favour of tenecteplase for more than 180 min and 1.77 (95% CI −2.66 to 6.20; p=0.58) for 0–180 min. Conclusions In AIS patients who were treated with either tenecteplase or alteplase within 4.5 hours onset, there was no difference observed in the efficacy and safety between the two groups at the three different OTT time intervals.


  • Open Access

    Gut Microbiome and Stroke: a Bidirectional Mendelian Randomisation Study in East Asian and European Populations

    by Shiyao Cheng, Hao Zheng, Yuandan Wei, Xingchen Lin, Yuqin Gu, Xinxin Guo, Zhe Fan, Hao Li, Si Cheng, Siyang Liu

    Background and aims: Observational studies have implicated the involvement of gut microbiome in stroke development. Conversely, stroke may disrupt the gut microbiome balance, potentially causing systemic infections exacerbated brain infarction. However, the causal relationship remains controversial or unknown. To investigate bidirectional causality and potential ethnic differences, we conducted a bidirectional two-sample Mendelian randomisation (MR) study in both East Asian (EAS) and European (EU) populations. Methods: Leveraging the hitherto largest genome-wide association study (GWAS) summary data from the MiBioGen Consortium (n=18 340, EU) and BGI (n=2524, EAS) for the gut microbiome, stroke GWAS data from the GIGASTROKE Consortium(264 655 EAS and 1 308 460 EU), we conducted bidirectional MR and sensitivity analyses separately for the EAS and EU population. Results: We identified nominally significant associations between 85 gut microbiomes taxa in EAS and 64 gut microbiomes taxa in EU with stroke or its subtypes. Following multiple testing, we observed that genetically determined 1 SD increase in the relative abundance of species Bacteroides pectinophilus decreased the risk of cardioembolic stroke onset by 28% (OR 0.72 (95% CI 0.62 to 0.84); p=4.22e−5), and that genetically determined 1 SD increase in class Negativicutes resulted in a 0.76% risk increase in small vessel stroke in EAS. No significant causal association was identified in the EU population and the reverse MR analysis. Conclusion: Our study revealed subtype-specific and population-specific causal associations between gut microbiome and stroke risk among EAS and EU populations. The identified causality holds promise for developing a new stroke prevention strategy, warrants further mechanistic validation and necessitates clinical trial studies.


  • Open Access

    Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial

    by Yunyun Xiong, Manjun Hao, Yuesong Pan, Chunmiao Duan, Xueyan Feng, Hao Li, Na Wu, Liyuan Wang, Xia Meng, Xingquan Zhao, et al.

    Background and purpose Recombinant human prourokinase (rhPro-UK) is a new generation of specific plasminogen activator, that is non-inferior to alteplase in acute ischemic stroke. We aimed to investigate the efficacy and safety of rhPro-UK compared with standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset. Methods and design Prourokinase in mild ischemic stroke is a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial. Patients who had an acute ischemic stroke within 4.5 hours from symptom onset and with baseline National Institutes of Health Stroke Scale (NIHSS) score ≤ 5 will be recruited. Patients will be randomly assigned (1:1) to receive intravenous rhPro-UK (35 mg) or standard medical treatment. The follow-up duration will be 90 days. The calculated sample size is 1446. Study outcomes Primary efficacy outcome is an excellent functional outcome, defined as a modified Rankin Scale (mRS) score ≤ 1 at 90 days. Secondary efficacy outcomes include ordinal distribution of mRS at 90 days, mRS score ≤ 2 at 90 days, early neurological improvement at 24 hours (a decrease of NIHSS score ≥ 4 points compared with baseline or NIHSS score ≤ 1 point), Barthel index of 75–100 points at 90 days, quality of life at 90 days, and activities of daily living at 90 days. Safety outcomes are symptomatic intracranial haemorrhage within 36 hours, mortality at 90 days, moderate and severe systematic bleeding at 90 days, and adverse events/serious adverse events within 90 days. Discussion This large phase III randomised clinical trial will answer the question of whether thrombolysis is beneficial for acute mild ischemic stroke, and may provide evidence for rhPro-UK in patients had an acute mild ischemic stroke within 4.5 hours of symptom onset. Trial registration number NCT05507645